COMP360 Psilocybin for TRD Brings Rapid Relief, Lasting Benefit | Steve Levine, MD
Автор: HCPLive
Загружено: 2026-02-20
Просмотров: 32
Описание:
In a phase 3 study, Compass Pathways' synthetic psilocybin therapy, COMP360, demonstrates next-day antidepressant effects and potential 6-month durability for treatment-resistant depression (TRD).
In this interview, Steve Levine, MD, chief patient officer at Compass Pathways, explains key findings from the phase 3 COMP005 and COMP006 trials, including the –3.8 MADRS point reduction vs control at week 6, rapid symptom improvement observed by day 2, and sustained benefits through 26 weeks with 1 or 2 doses.
Read more about the study here: https://www.hcplive.com/view/comp360-...
More MDD coverage: https://www.hcplive.com/clinical/majo...
Key Highlights:
00:07: Clinically meaningful difference on MADRS
0:44: Effect size of COMP006 vs other TRD trials
02:16: Rapid onset of COMP360
03:35: Maintaining benefit through week 6 after just 1 or 2 doses
04:19: 26-week COMP005 durability data
05:20: MADRS response rate
07:05: COMP360 vs esketamine
#TRD #treatmentresistantdepression #depression #mdd #psychedelictherapy
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
